Online First srb

Medicinska reč

Inflamatorni miofibroblastični tumor kolena sedmogodišnjeg dečaka: prikaz slučaja

https://doi.org/10.5937/medrec2504096J

UDC 616.718-006.03-002-053.5

Aleksandar Janković¹, Zoran Marjanović¹, Nikola Bojović¹, Nikola Vacić¹, Dejana Božić²

Klinika ze dečju hirurgiju, ortopediju i traumatologiju, Univerzitetski klinički centar Niš, Niš

Institut za zdravstvenu zaštitu majke i deteta „Dr Vukan Čupić“, Beograd, Srbija

Prikaz slučaja

Apstrakt

Inflamatorni miofibroblastični tumor (IMT) predstavlja retku mezenhimalnu neoplazmu intermedijernog biološkog potencijala, koja češće zahvata decu i mlade. Najčešće je lokalizovan u plućima i abdominopelvičnom predelu, ali može nastati u gotovo svakom organu. Prikazujemo slučaj sedmogodišnjeg dečaka sa ekstraartikularnom tumoroznom masom medijalnog aspekta desnog kolena. Radiološki (MRI) je lezija bila dobro ograničena, intenzivno homogeno pojačana nakon aplikacije kontrasta, bez invazije zgloba ili kosti. Lezija je u celosti hirurški uklonjena. Histopatološki nalaz je pokazao proliferaciju miofibroblasta u miksodnoj stromi sa izraženim inflamatornim infiltratom. Imunohistohemijski tumor je bio SMA pozitivan, ALK negativan; molekularno je dokazan rearanžman ROS1 i fuzija COL1A1–PDGFRα. Postoperativni tok protekao je bez komplikacija, bez recidiva na kontroli. Ovaj slučaj naglašava značaj sveobuhvatne molekularne dijagnostike u atipičnim lokalizacijama IMT-a i potencijal za ciljanu terapiju kod neresektabilnih ili rekurentnih formi.

Ključne reči: inflamatorni miofibroblastični tumor, koleno, dete, ROS1, PDGFRα, ALK-negativan

References

  1. Choi JH. Inflammatory Myofibroblastic Tumor: An Updated Review. Cancers (Basel) 2025;17(8):1327.
  2. Gros L, Dei Tos AP, Jones RL, Digklia A. Inflammatory Myofibroblastic Tumour: State of the Art. Cancers (Basel) 2022;14(15):3662.
  3. Siemion K, Reszec-Gielazyn J, Kisluk J, Roszkowiak L, Zak J, Korzynska A. What do we know about inflammatory myofibroblastic tumors? – A systematic review. Adv Med Sci 2022;67(1):129-38.
  4. Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives. Pathologica 2021;113(2):70-84.
  5. Chmiel P, Słowikowska A, Banaszek Ł, et al. Inflammatory myofibroblastic tumor from molecular pathology to targeted therapies. Oncol Res 2024;32(7):1141–62.
  6. Casanova M, Brennan B, Alaggio R, et al. Inflammatory myofibroblastic tumor: The experience of the European pediatric Soft Tissue Sarcoma Study Group (EpSSG). Eur J Cancer 2020;127:123-29.
  7. Da M, Qian B, Mo X, et al. Inflammatory Myofibroblastic Tumors in Children: A Clinical Retrospective Study on 19 Cases. Front Pediatr 2021;9:543078.
  8. Raitio A, Losty PD. Treatment and outcomes in pediatric inflammatory myofibroblastic tumors – A systematic review of published studies. Eur J Surg Oncol 2024;50(7):108388.
  9. Comandini D, Catalano F, Grassi M, et al. Outstanding Response in a Patient With ROS1-Rearranged Inflammatory Myofibroblastic Tumor of Soft Tissues Treated With Crizotinib: Case Report. Front Oncol 2021;11:658327.
  10. Mai S, Xiong G, Diao D, Wang W, Zhou Y, Cai R. Case report: Crizotinib is effective in a patient with ROS1-rearranged pulmonary inflammatory myofibroblastic tumor. Lung Cancer 2019;128:101-4.
  11. Yıldırım ÜM, Kebudi R, Zülfikar B, Bilgiç B. Inflammatory myofibroblastic tumor in children: clinical characteristics and treatment outcomes with a focus on targeted therapies. Turk J Pediatr 2025;67(1):51–60.
  12. Lovly CM, Gupta A, Lipson D, et al. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov 2014;4(8):889-95.
  13. Liu M, Zhu D. Two cases of inflammatory myofibroblastic tumor treated with targeted drugs: A case report. Medicine (Baltimore) 2024;103(21):e38136

Ceo tekst